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ComParative Cost-effeCtiveness of BeCaPlermin gel on wounD 
healing in Patients with DiaBetiC foot ulCer: Changes in wounD 
surfaCe area
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Objectives: Determine the cost-effectiveness of becaplermin gel for the treatment 
of diabetic foot ulcers (DFU) relative to good wound care (GWC) alone. MethOds: 
Wound surface area (WSA) reduction rates were used to predict the expected costs 
and outcomes of wound healing for becaplermin versus GWC cohorts over a 1-year 
time horizon. Changes in WSA were taken from the Phase 3 pivotal trials. The out-
comes of the analysis include the average percent reduction of baseline WSA, the 
direct costs of DFU therapy and the cost per centimeter squared of WSA reduction. 
The costs for becaplermin gel and DFU patient evaluation and management were 
derived from standard cost references. Becaplermin utilization was calculated using 
the manufacturer’s recommended dosing algorithm. The economic perspective was 
that of the payer. Costs are reported in 2013 US dollars. Results: The average WSA 
at baseline was 2.2 centimeters squared. At 20 weeks in the clinical study the beca-
plermin group demonstrated a statistically higher probability of complete wound 
closure compared to the GWC group (p= 0.015) at 50% versus 35%, respectively. Given 
the reported WSA reduction rates, becaplermin treated DFU were expected to close 
100% at 27 weeks while the GWC group reached an expected 88% reduction in WSA 
at 52 weeks. When costs were compared by wound closure rates, the cost per 1 
centimeter reduction in WSA was $1,285 in the becaplermin group compared to 
$3,446 in the GWC group. The total expected direct cost of DFU care across the 
1-year time horizon was estimated at $6,702 in the GWC group compared to $2,827 
in the becaplermin group. cOnclusiOns: DFU patients treated with becaplermin 
experienced better clinical outcomes than those treated with GWC alone. As a result 
of the improved outcomes becaplermin demonstrated economic dominance over 
GWC providing better outcomes at a lower direct cost.
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Objectives: Although metformin remained the mainstay of oral hypoglycemic 
agent (OHA), patients receiving combined OHAs significantly increased. We aimed 
to differentiate real-world effectiveness and economic benefit of metformin-based 
OHAs, from the perspective of Taiwan’s National Health Insurance (NHI). MethOds: 
The NHI Research Database 1999 – 2012 was used, which was derived from the 
claims of Taiwan NHI, a mandatory-enrollment and single-payment system cre-
ated in 1995, covering over 99% of the population. Four metformin-based cohorts 
were extracted: one reference group was metformin plus sulphonylureas (Met-SU), 
and three comparison groups were metformin plus acarbose (Met-ACA), metformin 
plus thiazolidinediones (Met-TZD), and metformin plus meglitidine. By using pro-
pensity scores, each comparison cohort subject was 1:1 matched to the reference 
subject on demographics and comorbidity. The effectiveness outcome of interest 
was diabetes associated cardiovascular disease (CVD) complication risk. Only direct 
medical costs were included (expressed in 2012 U.S. dollars). A Markov model was 
applied to project lifetime effectiveness and economic outcomes, discounted at 
3% per annum. Bootstrapping technique was used for assessing uncertainty in 
cost-effectiveness analyses. Results: The age-gender weighted average lifetime 
costs was $94,112.5, of which 61% was attributed to diabetic complications and the 
managing CVD accounted for 67% of total complication costs. The estimated CVD 
risk was 34%, with the highest in Met-SU and the lowest in Met-TZD (40% vs. 31%, 
p< .05). After a 10 year follow-up, average expenditure in Met-TZD was highest, due 
to higher drug acquisition price of TZD. However, over a lifetime, Met-ACA had the 
highest spending, most attributed to managing diabetic complications. The sensitiv-
ity analysis consistently demonstrated the cost-effectiveness of Met-TZD vs. other 
metformin-based therapies. cOnclusiOns: Over a lifetime, Met-TZD combina-
tion was the least expensive and most effective in lowering CVD risk. The results 
would inform clinical selection of “add-on” therapy in patients with inadequately 
controlled by metformin.
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Objectives: Metformin forms the first-line therapy for patients with type 2 dia-
betes, but the majority require treatment intensification at some stage due to the 
progressive nature of the disease. The 1860-LIRA-DPP4 trial showed that, at 52 weeks, 
liraglutide exhibited greater improvements compared with sitagliptin in HbA1c, 
blood pressure, serum lipids and BMI in patients with diabetes inadequately con-
trolled on metformin monotherapy. This study compared the long-term clinical 
and cost implications associated with liraglutide and sitagliptin for subjects with 
type 2 diabetes in Spain. MethOds: Data were taken from the 1860-LIRA-DPP4 trial 
randomized, controlled trial at 52 weeks, in which adults with type 2 diabetes were 
randomly allocated to receive either 1.8mg liraglutide or 100mg sitagliptin daily in 
addition to metformin. Long-term (patient lifetime) projections of clinical outcomes 
and direct costs (2012 EUR) were made using a published and validated model of 
type 2 diabetes. Outcomes were discounted at 3% annually. Sensitivity analyses 
were performed and support the findings. Results: Liraglutide was associated 
with improved clinical outcomes over sitagliptin in terms of life expectancy (14.24 
versus 13.87 years) and quality adjusted life-expectancy (9.24 versus 8.84 quality-
adjusted life years [QALYs]). Improved clinical outcomes were driven by improved 
of wound healing and amputation rates for becaplermin and non-becaplermin 
DFU cohorts over a 1-year time period. Outcome data used in the analysis were 
derived from a propensity score matched cohort of 24,898 subjects with DFU from 
the Curative Health Services database from 1998-2004 who were followed for 20 
weeks. Primary outcomes of interest were ulcer-free weeks and rates of amputa-
tion. Costs for amputation and becaplermin gel*were derived from standard cost 
references and medical supply wholesalers. Total weekly costs per episode of DFU 
care were estimated from a large retrospective claims database. Transition probabili-
ties for healing and amputation were derived from the aforementioned propensity 
score matched cohorts. Ulcer recurrence was estimated from the medical literature. 
Utilization for becaplermin was calculated using the manufacturer’s recommended 
dosing algorithm. The economic perspective taken was that of the payer. Costs are 
reported in 2013 US dollars. Results: Overall, 2,394 (9.6%) received becaplermin. 
Of those who received becaplermin, 33.5% healed at 20 weeks compared to 26.5% 
who did not receive becaplermin (p< 0.0001). In addition, the percent of patients 
requiring amputation were significantly (p< 0.0001) lower in the becaplermin cohort 
(4.9% versus 6.4%, respectively). Patients treated with becaplermin had substantially 
higher ulcer-free weeks compared to non-becaplermin patients (16.1 versus 12.5 
weeks, respectively). Expected annual direct costs for DFU were $20,885 for becapler-
min and $23,506 for non-becaplermin. cOnclusiOns: Becaplermin was economi-
cally dominant over standard therapy, providing better outcomes at a lower cost in 
patients with DFU. In addition, becaplermin is more effective in wound healing and 
preventing amputation, thereby decreasing long-term costs for DFU. *Regranex®, 
Smith & Nephew Biotherapeutics, Fort Worth, Texas
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Objectives: Determine the cost-effectiveness of small intestinal submucosa 
extracellular matrix (SISEM)* relative to human fibroblast-derived dermal sub-
stitute (HF-DDS)†on wound closure for the treatment of diabetic foot ulcers 
(DFUs). MethOds: A 2-stage Markov model was used to predict the expected costs 
and outcomes of wound closure for SISEM and HF-DDS. Outcome data used in the 
analysis were taken from a 12-week randomized clinical trial that directly com-
pared SISEM and HF-DDS. Twenty-six patients completed the study; 13 for SISEM 
and 13 for HF-DDS. The primary outcome of interest was ulcer-free days. Transition 
probabilities for the Markov states were estimated from the clinical trial. Resource 
utilization was based on the treatment regimen used in the clinical trial. Costs were 
derived from standard cost references and medical supply wholesalers. The eco-
nomic perspective taken was that of the payer. No cost discounting was performed 
due to the short duration of the study. Results: Ten wounds closed in the SISEM 
group (77%), with an average time to closure of 36 days, while 11 wounds closed 
in the HF-DDS group (85%), with an average closure time of 41 days. No significant 
difference was found in the time to closure or in the percentage of wound closure 
between the two groups (p= 0.73). Expected direct costs per patient for DFU were 
$2,949 for SISEM and $5,282 for HF-DDS. Patients treated with HF-DDS incurred 
total treatment costs that were approximately 1.8 times higher than those treated 
with SISEM. The estimated cost per ulcer-free day was more than 1.5 times higher 
HF-DDS vs. SISEM. cOnclusiOns: SISEM yielded similar outcomes at a lower cost 
in patients with DFU. Health care providers should consider SISEM as a cost-saving 
alternative to HF-DDS. *OASIS®, Smith & Nephew Biotherapeutics, Fort Worth, Texas 
†Dermagraft®, Shire Regenerative Medicine Inc., San Diego, California
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Objectives: Vildagliptin is a DPP-4 inhibitor available in Colombia for the treat-
ment of diabetes mellitus as monotherapy or in combination with metformin, 
sulfonylureas, or insulin. Our aim was to determine the cost-effectiveness of the 
addition of vildagliptin to metformin, or sulfonylureas for the management of 
type 2 diabetes in Colombia. MethOds: We developed a hybrid decision Markov 
model to simulate the level of glycemic control and the health states associated 
with macrovascular complications (myocardial infarction, disabling stroke, and 
heart failure), nephropathy and death in a hypothetic cohort of patients with type 
2 diabetes. Transition probabilities and utilities were derived from published trials 
and validated with local clinical experts. Costs were calculated based on resource 
use from local clinical guidelines and databases from the Ministry of Health and 
private institutions. The base case was developed based on the demographic char-
acteristics of patients with type 2 diabetes in Colombia with a mean age of 59 
years. The analysis was performed from the payer perspective for a time horizon 
of 20 years. Multivariate sensitivity analysis was performed. Results: Our results 
show that the addition of vildagliptine to metformine yielded an incremental 
effectiveness of 0.83 QALY’s over the 20 years of this cohort when compared to 
metformine alone. The addition of vildagliptine to metformine + glimepiride com-
bination yielded an minor increase in QALY’s of only 0.27. Incremental cost for 
the addition of vildagliptine to metformine was $COP 3,626,000 ($1,900 USD). The 
incremental cost of the addition of vildagliptine to the combination of metform-
ine was $COP 9,713,169 ($5,100 USD). The ICER for the addition of vildagliptine to 
metformine was $COP 4,358,350 ($2,500 USD) and to metformine + glimepiride 
was $ COP 35,697,647 ($18,700 USD). cOnclusiOns: The addition of vildagliptine 
to metformine and metformine+glimepiride is a cost-effective alternative for the 
treatment of diabetes type 2 in Colombia.
